Patents Examined by Nizal S. Chandrakumar
  • Patent number: 11560376
    Abstract: The invention relates to compounds of formula (A) and formula (I): or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: January 24, 2023
    Assignee: Pliant Therapeutics, Inc.
    Inventors: Jacob Cha, Chengguo Dong, Timothy Hom, Lan Jiang, Katerina Leftheris, Hui Li, David John Morgans, Jr., Manuel Munoz, Maureen Reilly, Yajun Zheng, Christopher Bailey, Darren Finklestein
  • Patent number: 11554126
    Abstract: Compositions comprising bile acids or their salts and methods of use thereof for the treatment of residual lesions of vascular anomalies.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: January 17, 2023
    Assignees: Georgetown University, MedStar Health
    Inventors: Cynthia Marie Carver Deklotz, Michael Andrew Cardis
  • Patent number: 11547714
    Abstract: The present disclosure pertains to pharmaceutically acceptable salts of fospropofol and their use to treat migraine.
    Type: Grant
    Filed: February 5, 2021
    Date of Patent: January 10, 2023
    Inventors: Randall B. Murphy, Steven L. Krill, Samuel Andrew
  • Patent number: 11547704
    Abstract: The invention is directed to substituted piperidine derivatives. Specifically, the invention is directed to compounds according to Formula IIII: wherein A, B, X, Y, L1, L2, L3, R1, R2, R3, R4, R5, R6, R9, z2, z4, z5, and z6 are as defined herein, and salts thereof.
    Type: Grant
    Filed: June 11, 2020
    Date of Patent: January 10, 2023
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Jeffrey Michael Axten, Mui Cheung, Michael P. Demartino, Hilary Schenck Eidam, Raghava Reddy Kethiri, Biswajit Kalita
  • Patent number: 11547691
    Abstract: Described herein are Dendrilla membranosa compounds and derivatives thereof. Also described herein are formulations that can contain an amount of one or more Dendrilla membranosa compounds or derivatives thereof and a carrier. Also described herein are methods of administering one or more Dendrilla membranosa compound and/or derivative thereof or a formulation thereof to a subject in need thereof.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: January 10, 2023
    Inventors: Bill J. Baker, Lindsey N. Shaw, Andrew Jason Shilling, Alexandre Jean Bory, Jessie Allen (Adams), Charles Dunkle Amsler, Jr., James Bruce McClintock
  • Patent number: 11535523
    Abstract: According to this method, a fatty acid of CnH2nO2 (n=5 to 14) is mixed with a plurality of metal sources selected from Zn, In, Sn, Sb, and Al, thereby fatty acid metal salts are obtained, subsequently the fatty acid metal salts are heated at 130° C. to 250° C., and a metal soap that is a precursor is obtained. This precursor is heated at 200° C. to 350° C., and metal oxide primary particles are dispersed in the precursor melt. To this dispersion liquid, a washing solvent having a ?P value higher by 5 to 12 than the ?P value of the Hansen solubility parameter of the final dispersing solvent is added, thereby the metal oxide primary particles are washed and agglomerated, metal oxide secondary particles are obtained, and then washing is repeated.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: December 27, 2022
    Inventor: Satoko Higano
  • Patent number: 11530175
    Abstract: The invention discloses a method for the preparation of fluoro alkylated compounds by homogeneous Ni catalyzed fluoro alkylation with fluoro alkyl halides in the presence of a base.
    Type: Grant
    Filed: February 20, 2020
    Date of Patent: December 20, 2022
    Assignee: ARXADA AG
    Inventors: Christoph Taeschler, Stefan Ellinger, Florencio Zaragoza Doerwald, Matthias Beller, Helfried Neumann, Florian Fischer, Shaoke Zhang, Nicolas Rotta-Loria
  • Patent number: 11529346
    Abstract: A composition having gel-like consistency contains metronidazole, terconazole, a physiologically acceptable thickener and water. The composition is useful for treating bacterial vaginosis as well as vulvovaginal candidiasis.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: December 20, 2022
    Assignee: National Medical Supply, LLC
    Inventors: Robert J. Borgman, James E. Juul
  • Patent number: 11524009
    Abstract: The present disclosure provides pharmaceutical combinations comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2, BCL2/BCLxL, and BCLxL inhibitors. Also provided are methods of treating cancer comprising administering a therapeutically effective amount of at least one spliceosome modulator and a therapeutically effective amount of at least one inhibitor chosen from BCL2, BCL2/BCLxL, and BCLxL inhibitors.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: December 13, 2022
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Daniel Aird, Laura Corson, Ping Zhu, Markus Warmuth, Silvia Buonamici, Peter Gerard Smith, Peter Fekkes
  • Patent number: 11518849
    Abstract: Techniques regarding post polymerization modifications to polycarbonate polymers via a flow reactor are provided. For example, one or more embodiments described herein can comprise a cyclic carbonate monomer that can be employed to facilitate polymerization of one or more polycarbonate platforms susceptible to post polymerization modification. For instance, one or more embodiments can regard a cyclic carbonate molecular backbone covalently bonded to an aryl halide functional group via in accordance with a chemical structure selected from the group consisting of: In the chemical structures, “R1” can be selected from the group consisting of a hydrogen atom and a functional group comprising a first alkyl group; “L” can represent a linkage group, comprising: a second alkyl group and an end group having at least one member selected from the group consisting of an oxygen atom and a nitrogen atom; and “A” can represent the aryl halide functional group.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: December 6, 2022
    Inventors: Nathaniel H. Park, Victoria A Piunova, Dmitry Zubarev, James L. Hedrick, Yi Yan Yang, Eddy Wei Ping Tan
  • Patent number: 11510921
    Abstract: The present disclosure describes pharmaceutical formulations of bromocriptine and methods of manufacturing and using such formulations. The formulations are useful for treating physiological disorders including improving glycemic control in the treatment of type 2 diabetes. Also disclosed is synthesis of bromocriptine citrate, and compositions and dosage forms containing bromocriptine citrate.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: November 29, 2022
    Assignee: VeroScience LLC
    Inventor: Anthony H. Cincotta
  • Patent number: 11510915
    Abstract: An antitumor formulation comprising a biphenyl compound having LSD1 inhibitory activity or a salt thereof and one or more other antitumor agents that are administered in combination, the compound being represented by Formula (I): wherein ring A, ring B, R1 to R6, l, m, and n are as defined in the specification.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: November 29, 2022
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventor: Akiko Osada
  • Patent number: 11510912
    Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds, and methods of using such compounds for treatment of joint damage or joint injury in a mammal, and for inducing differentiation of mesenchymal stem cells into chondrocytes.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: November 29, 2022
    Assignee: Novartis AG
    Inventors: Ha-Soon Choi, James Paul Lajiness, Srinivasa Reddy Natala, Bao Nguyen, Hank Michael James Petrassi, Zhicheng Wang
  • Patent number: 11504334
    Abstract: Described herein are synthetic progestogens, such as 6?,7?:15?,16?-Dimethylene-3-oxo-17?-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
    Type: Grant
    Filed: July 1, 2022
    Date of Patent: November 22, 2022
    Inventors: Philippe Perrin, Jose Luis Velada, Dominique Drouin
  • Patent number: 11504385
    Abstract: It discloses a proteolysis targeting chimeric molecule, a preparation method and an application thereof. The proteolysis targeting chimeric molecule provided by the disclosure can inhibit the expression of BCR-ABL and/or CRBN protein in BCR-ABL and/or CRBN positive leukemia K562 cells to varying degrees, and thus can be used to prepare drugs for treating BCR-ABL and/or CRBN positive leukemia, wherein the proteolysis targeting chimeric molecule with n=3 has excellent photo-isomerization activity, and can be used in preparation of the reagents or drugs for light-regulated degradation of BCR-ABL and/or CRBN protein. The disclosure also provides a method for synthesizing the series of proteolysis targeting chimeric molecules.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: November 22, 2022
    Inventors: Qidong You, Zhengyu Jiang, Yan Wang, Yuhui Jin, Mengchen Lu, Xiaoli Xu, Xiaoke Guo
  • Patent number: 11505544
    Abstract: The present invention relates to a new process for preparing quinoline compounds of the general formula (II): in which Q, A, R4, R3 and R3?, are as defined herein, as well as to the intermediate compounds of said new process.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: November 22, 2022
    Assignee: Bayer Animal Health GMBH
    Inventors: Florian Erver, Frank Memmel, Thomas Himmler, Andreas Karl Steib, Marc Nowakowski
  • Patent number: 11498901
    Abstract: Described herein are catalytic hydrogenation and the use of ruthenium complexes having a bidentate diphosphine ligand or two monodentate phosphine ligands, two carboxylate ligands, and optionally a diamine ligand in hydrogenation processes for the reduction of imines into the corresponding amines.
    Type: Grant
    Filed: February 18, 2019
    Date of Patent: November 15, 2022
    Assignee: FIRMENICH SA
    Inventor: Lionel Saudan
  • Patent number: 11497727
    Abstract: A method of producing a cannabinoid nanoparticle carrier composition for administration to a human, including the steps of incorporating non-ionic surfactants with cannabinoid oils and lipids; inducing sonication for a predetermined period of time at a predetermined amplification with a ultrasonic liquid processor until completely integrated; dissolving ascorbic acid into a carrier fluid; combining in sequence the non-ionic surfactants, lipids, and cannabinoids with a carrier fluid consisting of distilled water and ascorbic acid; sonicating using an ultrasonic liquid processor at predetermined amplitude for a predetermined period of time at a controlled temperature.
    Type: Grant
    Filed: July 8, 2020
    Date of Patent: November 15, 2022
    Inventor: Aaron Miles
  • Patent number: 11491154
    Abstract: The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to mustard-based alkylating agents such as uracil mustard and analogs, derivatives, or prodrugs thereof, including 6-methyluracil mustard and 6-ethyluracil mustard.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: November 8, 2022
    Inventor: Dennis M. Brown
  • Patent number: 11492334
    Abstract: A method for producing a nitroso compound of the following formula (3), comprising reacting a compound of the following formula (1) with a compound of the following formula (2) by using a tertiary alcohol and a base. wherein R1, R2, R3, R4, R5, R6, R7, R8, and R9 are each independently a hydrogen atom, a halogen atom, a (C1-C4) alkyl, or a (C1-C4) alkoxy.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: November 8, 2022
    Assignee: Kumiai Chemical Industry Co., Ltd.
    Inventors: Ryuji Tamai, Yukio Uchida, Fumiaki Takabe, Akira Kato, Ryo Maruyama, Ryo Kobayashi